Advancing the future of aortic valve reconstruction through surgical innovation and novel device technologies. Recognized as one of eight leading innovators shaping the future of cardiothoracic surgery.
AVaTAR MedTech was honored to participate in the 4th Innovation Summit hosted by EACTS – European Association for Cardio-Thoracic Surgery (23–25 April 2026), a leading international forum bringing together surgeons, engineers, scientists, and innovators to shape the future of cardiothoracic surgery.
Being selected as one of the eight finalists featured during the Innovation Summit represents an important milestone for AVaTAR MedTech and reinforces our commitment to advancing next-generation solutions for aortic valve reconstruction.
During the event, our Chief Scientific Officer, Ignacio Lugones, presented:
“AVaTAR (Aortic Valve Autologous Trileaflet Anatomical Reconstruction): A Set of Surgical Devices to Reconstruct the Aortic Valve.”
Through this presentation, AVaTAR MedTech shared its vision for redefining aortic valve treatment through surgical innovation, personalized reconstruction strategies, and novel medical device technologies designed to improve long-term patient outcomes.
Our approach combines advanced surgical techniques with patient-specific reconstruction concepts to move toward a future where valve treatment becomes more durable, personalized, and adaptable to each individual’s anatomy and physiology.
Participating in EACTS Innovation Summit 2026 provided a valuable opportunity to exchange ideas with global leaders in cardiovascular surgery, medical technology, and translational innovation, further strengthening our mission to transform the future of structural heart treatment.
